Compare AbCellera Biologics Inc (ABCL) vs Ferrari NV (RACE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Ferrari NV — how do they compare? AbCellera Biologics Inc trades at $7.23 (market cap $2.35B), while Ferrari NV trades at $374.73 (market cap $67.98B). The key difference: Ferrari NV is far larger — about 28.9× AbCellera Biologics Inc's market cap, and Ferrari NV pays a 1.09% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | RACE | |
|---|---|---|
Market Cap | $2.35B | $67.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $517.65 |
52-Week Low | $2.78 | $314.63 |
Enterprise Value | $1.99B | $69.19B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Ferrari (RACE) trades at $386.99, up 0.52% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, a 22.19% net margin, and robust cash flow. Recent news highlights the company's ongoing share buyback program and strategic moves like the new V12 model and EV developments. Analyst sentiment remains positive with a $467.50 consensus target.
The outlook is favorable given Ferrari's pricing power and hybrid sales growth, but risks include EV market reception and economic sensitivity. Wall Street's strong buy consensus (72% buy ratings) supports upside potential, though high valuation multiples warrant caution amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
